The success of viral vectors mediated gene therapy is still hampered by immunogenicity and insufficient transgeneexpression. Alternatively, non-viral vectors mediated gene delivery has the advantage of low immunogenicity despiteshowing low transgene expression. By carefully considering the advantages of each approach, hybrid vectors are currentlybeing developed by modifying the viral vectors using non-viral biopolymers. This review provides an overview of thehybrid vectors currently being developed.
Volume 44 | Issue 5
Click here for Editorial Note on CAP Mode